BLU GIST
21 Dec 2020
VOYAGER
NCT03465722
Study of Avapritinib (BLU-285) vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Cancer Type | Stomach & Oesophageal |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2021-03-26 |
Anticipated End Date | 2023-04-01 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Amitesh Roy |
Recruitment Status | Recruitment on Hold |